https://www.selleckchem.com/pr....oducts/sitravatinib-
5% vs 4.2%) (P .0001). Patients with recurrent NAFLD more often had myocardial infarction compared with those without recurrence (8.3% vs 0%) (P=.0313). Five years after LT, cardiovascular morbidity was more frequent in the NAFLD group than in the HCV group (12.8% vs 9.3%) (P=.0256), whereas no difference in overall survival was observed. LT for NAFLD is associated with satisfactory 5-year outcomes; however, our data underscore the need for close monitoring and aggressive management of cardiovascular risk factors in th
Like
Comment
Share
